Role of Fcγ receptors in HER2-targeted breast cancer therapy
Several therapeutic monoclonal antibodies (mAbs), including those targeting epidermal growth factor receptor, human epidermal growth factor receptor 2 (HER2), and CD20, mediate fragment crystallizable gamma receptor (FcγR)–dependent activities as part of their mechanism of action. These activities i...
Saved in:
Main Authors: | Hope S Rugo, Antonino Musolino, William J Gradishar, Jeffrey L Nordstrom, Edwin P Rock, Fernanda Arnaldez, Mark D Pegram |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2022-01-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/10/1/e003171.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugs
by: Xiang Zhang, et al.
Published: (2025-02-01) -
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy
by: Luca Mastrantoni, et al.
Published: (2025-02-01) -
Clinical characteristics, metastasis patterns, and treatment outcomes of HER2-low breast cancer
by: Maria Elena Lacruz, et al.
Published: (2025-02-01) -
A multicenter retrospective study of early cardiac toxicity in operable breast cancer patients receiving concurrent dual or mono anti-HER2 therapy with postoperative radiation therapy
by: Jing Yang, et al.
Published: (2025-02-01) -
Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient
by: Nu T. Lu, et al.
Published: (2015-09-01)